Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Two classes of newer anti-hyperglycemic agents can reduce CV risk and events in patients with T2D, namely glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors
As seen with conventional drugs like troglitazone and ketoconazole, hepatotoxicity can be difficult to predict
Yet for millions of Medicare beneficiaries, these drugs have largely been out of reach
the methyl group at the 1-position and the amino group at the 5-position appear important for inhibitory activity
it learns how to maintain it
US$ 28.17
US$ 26.78
)
US$ 24.71
